Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04077723 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 498 | Hoffmann-La RocheINDUSTRY | 12 | Aug 27, 2026 | clinicaltrials |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Aug 27, 2026 |
| clinicaltrials |
| NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | active not recruiting | Phase 1 / Phase 2 | 62 | Massachusetts General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05700084 | Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 84 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05937269 | Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship | active not recruiting | Phase 1 | 14 | The University of Texas Health Science Center, HoustonOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06299124 | A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors | active not recruiting | Phase 1 | 40 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT01959698 | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 29 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03448042 | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | active not recruiting | Phase 1 | 123 | Genentech, Inc.INDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT04288726 | Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | active not recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05236036 | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | active not recruiting | Phase 1 | 86 | Northwestern UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05367440 | Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer(PETRANHA) | active not recruiting | Phase 1 / Phase 2 | 174 | AstraZenecaINDUSTRY | 4 | Aug 26, 2026 | clinicaltrials |
| NCT06577987 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | active not recruiting | Phase 1 | 220 | Circle PharmaINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07166419 | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT01327781 | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04874480 | Tegavivint for the Treatment of Relapsed or Refractory Leukemia | active not recruiting | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05460767 | Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma | active not recruiting | Phase 1 | 504 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06818812 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | active not recruiting | Phase 1 | 30 | Incyte CorporationINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | active not recruiting | Phase 1 | 21 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT00463814 | AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies | active not recruiting | Phase 1 | 58 | AstraZenecaINDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT01297764 | A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma(QUAD) | active not recruiting | Phase 1 / Phase 2 | 17 | Hackensack Meridian HealthOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Mayo ClinicOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04073745 | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 50 | Roswell Park Cancer InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04158739 | Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 16 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04214392 | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | active not recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05546580 | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)(FRIDA) | active not recruiting | Phase 1 | 50 | Oryzon Genomics S.A.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06590857 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.(TRACY-1) | active not recruiting | Phase 1 / Phase 2 | 16 | RayzeBio, Inc.INDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT07411586 | Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02160015 | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03150329 | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | active not recruiting | Phase 1 | 52 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03655002 | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03740334 | Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL | active not recruiting | Phase 1 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03884998 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | active not recruiting | Phase 1 / Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04106219 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | active not recruiting | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer(PAveMenT) | active not recruiting | Phase 1 | 45 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04535401 | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | active not recruiting | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04576091 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | active not recruiting | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT07209241 | Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07779031 | A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT(TP53) | active not recruiting | Phase 1 / Phase 2 | 58 | Liping DouOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | active not recruiting | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00977457 | Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery | active not recruiting | Phase 1 | 1,045 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02879695 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | active not recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04007029 | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04457232 | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation(FAPI PET Prost) | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04572451 | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma | active not recruiting | Phase 1 | 50 | Yana NajjarOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2026source: clinicaltrials